A Multicenter Randomized Phase II Study of Second Line Chemotherapy With Epirubicin( Farmorubicin) Versus the Pegylated Liposomal Doxorubicin in Advanced Breast Cancer Patients
To compare the efficacy of pegylated liposomal doxorubicin versus epirubicin as second line
chemotherapy in patient with advanced breast cancer
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Assessment of antitumor efficacy by objective tumor response rates
Objective responses confirmed by CT or MRI (on 3rd and 6th cy)
No
Dimitris Mavrudis, MD
Principal Investigator
University Hospital of Crete
Greece: National Organization of Medicines
CT/03.12
NCT00431795
June 2003
June 2012
Name | Location |
---|